Affiliation:
1. Faculty of Medicine, Department of Internal Medicine, Division of Nephrology Harran University Şanlıurfa Turkey
2. Faculty of Medicine, Department of Internal Medicine, Division of Nephrology Hacettepe University Ankara Turkey
Abstract
AbstractIntroductionPatients on hemodialysis, especially with diabetes, face elevated cardiovascular events. A major contributor to complications associated with diabetes is advanced glycation end products (AGEs). Removing these compounds is challenging in traditional hemodialysis. Medium‐cut‐off (MCO) membranes potentially remove toxins without significant albumin loss. This study explored how MCO membranes impact AGEs levels in uncontrolled diabetic patients undergoing hemodialysis.MethodsSixteen patients received MCO membrane dialysis, while others used high‐flux (HF) membranes. After 12 sessions, the dialyzers were switched, totaling 24 sessions. Blood samples at trial initiation (T0), session 12 (T1) and session 24 (T2) tested for CML, Pentosidine, laboratory parameters.ResultsSwitching dialyzers showed increased albumin with MCO‐to‐HF and decreased with HF‐to‐MCO, albeit nonsignificant (p = 0.5/p = 0.1). Patients on MCO had lower albumin levels than HF (p = 0.03/p = 0.6, respectively). Hemodialysis with MCO demonstrated lower levels of CML/Pentosidine compared to HF (p = 0.09/p = 0.9 for CML; p = 0.04/p = 0.3 for Pentosidine). Transitioning to HF led to elevated levels (p = 0.4/p = 0.09 for CML; p = 0.3/p = 0.07 for Pentosidine).ConclusionMCO dialysis in diabetic individuals notably reduces AGE levels.